Real-World Costing Analysis for Diffuse Large B-Cell Lymphoma in British Columbia | Zendy

Sarah Costa | Zendy; David W. Scott | Zendy; Christian Steidl | Zendy; Stuart Peacock | Zendy; Dean A. Regier | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Real-World Costing Analysis for Diffuse Large B-Cell Lymphoma in British Columbia

Author(s) -

Sarah Costa,

David W. Scott,

Christian Steidl,

Stuart Peacock,

Dean A. Regier

Publication year - 2019

Publication title -

current oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.053

H-Index - 51

eISSN - 1718-7729

pISSN - 1198-0052

DOI - 10.3747/co.26.4565

Subject(s) - medicine , confidence interval , cohort , diffuse large b cell lymphoma , inverse probability weighting , activity based costing , emergency medicine , lymphoma , propensity score matching , marketing , business

Diffuse large B-cell lymphoma (dlbcl) accounts for 30%-40% of all non-Hodgkin lymphomas. Approximately 60% of patients are cured with standard treatment. Targeted treatments are being investigated and might improve disease outcomes; however, their effect on cancer drug budgets will be significant. For the present study, we conducted an analysis of real-world costs for dlbcl patients treated in British Columbia, useful for health care system planning.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research